Inclusion Criteria:

- 18 years or older.

- Histologically confirmed, unresectable, locally advanced or metastatic colorectal
adenocarcinoma (stage III and IV), not amenable to curative surgery or radiotherapy.

- Intolerant of oxaliplatin and/or irinotecan, as demonstrated by unacceptable toxicity
after a trial of these agents as first-line therapy, or in the opinion of the
Investigator, be judged at high risk for unacceptable toxicity to oxaliplatin and/or
irinotecan,

- Presence of at least 1 measurable lesion,

- Have a life expectancy of at least 4 months.

- Women of childbearing potential, have a negative serum pregnancy test at screening
and Day 1 treatment and agree to practice abstinence or use an effective method of
contraception.

Exclusion Criteria:

- Central nervous system metastasis.

- Bony metastasis as the sole metastasis.

- Received any prior first-line chemotherapy for colorectal cancer.

- Previously exposed to DAVANAT® or Avastin®.

- Known or clinically suspected infection with HIV.

- Participated within 30 days or will participate concurrently in another
investigational drug or vaccine study.

- History of drug or alcohol dependence in the past 3 years.

- Other serious, non-malignant, significant, acute or chronic medical or psychiatric
illness that in the judgment of the Investigator could compromise subject safety,
limit the subject's ability to complete the study, and/or compromise the objectives
of the study.